Literature DB >> 8598451

CD40 ligand is expressed and functional on activated neonatal T cells.

J B Splawski1, J Nishioka, Y Nishioka, P E Lipsky.   

Abstract

Deficient CD40 ligand (CD40L) expression by neonatal T cells has been proposed to explain the diminished Ig production by newborns. Therefore, we examined the expression and function of CD40L on activated neonatal CD4+ T cells isolated from cord blood. Anti-CD3 activation of neonatal T cells resulted in the expression of CD40L demonstrated with specific mAb or a soluble CD40.G1 construct. The level of expression was comparable to that of adult memory CD4+ T cells. In contrast, PMA and ionomycin induced only minimal CD40L expression by neonatal T cells, whereas adult memory T cells expressed CD40L comparably after stimulation with PMA and ionomycin or anti-CD3. The expression of CD40L was blocked by cyclosporine and prostaglandin E2 (PGE2). IL-2 IL-4 partially reversed the inhibition of CD40L expression by cyclosporine, and IL-2 reversed the inhibition by PGE2. CD40L expressed by neonatal T cells was functionally active, since neonatal T cell-dependent production of IgG4 and IgE was inhibited by a soluble CD40.G1 construct. Moreover, neonatal T cells supported the secretion of significantly more IgG, IgA, and IgE than CD40L-deficient hyper-IgM T cell clones. In addition, neonatal CD4+ T cells induced CD86 B7-2) expression by neonatal B cells that was blocked by anti-CD40L but not by control mAb. The results indicate that neonatal T cells activated through the TCR/CD3 complex express CD40L and use it to promote CD86 expression, Ig secretion and heavy chain isotype switching by neonatal B cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598451

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.

Authors:  K E Balashov; D R Smith; S J Khoury; D A Hafler; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 5.  T cell-mediated immune responses in human newborns: ready to learn?

Authors:  A Marchant; M Goldman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Multiple cytokines sharing the common receptor gamma chain can induce CD154/CD40 ligand expression by human CD4+ T lymphocytes via a cyclosporin A-resistant pathway.

Authors:  J D Fayen
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

7.  Influence of atopic heredity on IL-4-, IL-12- and IFN-gamma-producing cells in in vitro activated cord blood mononuclear cells.

Authors:  S Gabrielsson; A Söderlund; C Nilsson; G Lilja; M Nordlund; M Troye-Blomberg
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

8.  Induction of functional CD154 (CD40 ligand) in neonatal T cells by cAMP-elevating agents.

Authors:  A Suárez; L Mozo; A Gayo; A Simó; C Gutiérrez
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

9.  Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome.

Authors:  K Agematsu; H Nagumo; K Shinozaki; S Hokibara; K Yasui; K Terada; N Kawamura; T Toba; S Nonoyama; H D Ochs; A Komiyama
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Potential immaturity of the T-cell and antigen-presenting cell interaction in cord blood with particular emphasis on the CD40-CD40 ligand costimulatory pathway.

Authors:  P Han; T McDonald; G Hodge
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.